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English speaker; 4) comparison of original and back translation;
and 5) review by a clinician. RESULTS: Cultural and linguistic
challenges emerged during the process. On the cultural level, the
differences in the approach to suicide and its methods based on
differences in tradition and availability of means required ﬁnding
suitable alternatives in the target languages.On the linguistic level,
it was important to differentiate between medical and psychiatric
hospitalisation after a suicide attempt and appropriate solutions
across languages had to be found. The process revealed an area of
ambiguity in the original rating instructions which had to be
clariﬁed in the translations. Examples of these and other chal-
lenges and their solutions will be discussed in the presentation.
CONCLUSIONS: The 45 language versions, of the C-SSRS (a
total of over 90 translations now exist), were established accord-
ing to a rigorous methodology to ensure conceptual equivalence
and cultural relevance across languages. The translations may
now be used in international studies to assess suicidal ideation and
behaviour and facilitate the comparison and pooling of data. The
analysis of the psychometric results will be necessary to see if and
how suicidal ideation and behaviour compare across countries
and cultures.
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INTRODUCTION: The EMEA reﬂection paper on HRQL
speciﬁes that the claim in the Summary of Product Characteris-
tics (SmPC) with respect to HRQL will always be considered
depending on the strength of the evidence, which should be
based on 6 criteria, amongst these are the justiﬁcation of the
choice of the HRQL instrument(s), and the evidence of valida-
tion (including for translation). To meet these requirements,
users should have access to reliable and updated information. To
determine if these can be met, it is necessary to review how users
access information about HRQL instruments. OBJECTIVES: 1)
To investigate how developers organize the release of informa-
tion about their instrument; 2) to comment on the pros and cons
for each identiﬁed dissemination strategy; 3) To make recom-
mendations for instrument developers to facilitate users’ access
to information. METHODS: we conducted a review of the
2,850 information requests addressed to our Information
Resources Centre in 2007. The requests were categorized
according to the type of information needed: 1) information
about the original instrument; 2) conditions of access/use of
instruments/translations; 3) validity of instruments/translations;
4) translation certiﬁcation; 5) intellectual property. To address
these, we made 900 contacts with developers, translators, pub-
lishers and other licensing authorities. RESULTS: Out of the
dissemination strategies identiﬁed and reviewed, ﬁve trends
emerged between two extremes: 1) uncontrolled, de-centralized,
free access to non-updated information without developer’s
input; 2) controlled, copyright-protected, centralized, fee-paying
access to reliable and updated information with developer’s
input. Advantages and disadvantages of strategies will be dis-
cussed. Examples demonstrate that the controlled strategy is
more compliant with the EMEA evidence requirements. CON-
CLUSION: Findings indicate that how a user can comply or not
with the EMEA requirements is directly related to how develop-
ers organize the release of information about their questionnaire
and translations. Promoting a controlled, centralized system
with developers’ input may facilitate access to reliable and
updated information.
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OBJECTIVES: To determine if the European Organization for
Research and Treatment of Cancer Quality of Life Question-
naire (EORTC QLQ-C30) can satisfactorily predict EQ-5D,
SF-6D and 15D utilities. The QLQ-C30 measures health-related
quality of life (HRQOL) using a global scale, ﬁve functional
scales and eight symptom scales/items and like most HRQOL
instruments provides a proﬁle of scores instead of an overall
preference-based index, precluding its use in cost-utility studies.
METHODS: A stratiﬁed sample (N = 48) of gastrointestinal
cancer patients on chemotherapy was interviewed. The survey
contained the QLQ-C30, the SF-36, two multi-attribute utility
instruments (EQ-5D and 15D) and socio-demographic and
disease-related questions. Validity of QLQ-C30 scales was
assessed by testing a priori hypotheses that they would be mod-
erately or strongly correlated with SF-36 scales measuring
similar HRQOL dimensions and that younger subjects and those
not reporting comorbid conditions would have better scores.
Linear regression analyses identiﬁed the extent to which QLQ-
C30 scales could predict EQ-5D, SF-6D and 15D utilities.
RESULTS: Pearson’s correlations between similar QLQ-C30
and SF-36 scales ranged from 0.69 to 0.89 (P < 0.001). Subjects
with coronary heart disease had worse scores on all QLQ-C30
functional scales (T-test, P < 0.05 for four scales), as did older
subjects as well (ANOVA, P < 0.05 for ﬁve scales). QLQ-C30
global, functional and symptom scales were signiﬁcant predic-
tors of utility scores elicited from standard instruments. Speciﬁ-
cally, three scales were signiﬁcant (P < 0.05) predictors of
EQ-5D utilities, six scales (P < 0.05) of SF-6D utilities and four
scales (P < 0.001) of 15D utilities and explained large portions
of variance (adjusted R2 was 0.610, 0.833 and 0.912 respec-
tively). Robustness of results was tested and conﬁrmed in patient
subgroups with differing HRQOL. CONCLUSIONS: Prelimi-
nary evidence has been provided supporting the appropriateness
mainly of the 15D and SF-6D instruments in cancer-speciﬁc
cost-utility studies, although further studies involving larger and
more diverse patient samples are encouraged.
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OBJECTIVES: Therapies may reduce short-term rates of non-
fatal myocardial infarction (MI) while having no detectable effect
on in-trial mortality. We sought to estimate the clinical beneﬁt of
preventing a non-fatal MI in terms of its effects upon long-term
rates of death and MI. METHODS: We analyzed 14,890 patients
with signiﬁcant coronary artery disease (CAD) undergoing diag-
nostic catheterization (cath) at Duke Medical Center between
1999 and 2006, with follow-up through June 2007. Patients
were classiﬁed as having a non-fatal MI within three months of
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their index cath (MI Group) or as being event-free at three
months (No MI Group). Outcomes through four years were
assessed in landmark analyses using Cox proportional hazards
techniques. RESULTS: Patients in the MI vs. No MI Groups had
a median of 4.2 years follow-up and were similar in age (62 vs.
63 years, p = .44), female sex (35% vs. 33%, p = .35), history of
hypertension (69% vs. 68%, p = .77), history of diabetes (35%
vs. 30%, p = .08), and in multi-vessel CAD (61% vs. 58%,
p = .17). At four years follow-up, patients in the MI vs. No MI
Groups had higher unadjusted rates of death (25% vs. 17%,
p < .001) and death or MI (34% vs. 21%, p < .001). After
adjustment, the hazards of death for patients in the MI vs.
No-MI Groups (HR 1.62; 95% CI 1.30, 2.02; p < .001) and
death or MI (HR 1.84; 95% CI 1.51, 2.24, p < .001) remained
signiﬁcant. When we extended the landmark period from three to
six months after the index cath, the adjusted hazards of death
(HR 1.61; 95% CI 1.34, 1.93; p < .001) and death or MI (HR
1.86; 95% CI 1.58, 2.19; p < .001) were still signiﬁcant. CON-
CLUSIONS: Non-fatal myocardial infarctions signiﬁcantly
increase subsequent rates of death and death or MI in CAD
patients. These ﬁndings suggest a long-term clinical beneﬁt for
therapies that avert non-fatal MIs.
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OBJECTIVES: To assess AF-QoL questionnaire performance in
patients with Atrial Fibrillation (AF) in a usual clinical practice
setting. METHODS: Observational, prospective, multicenter
studywas carried out in 29 Spanish centres. AF diagnosed patients
aged 18 who have changed a clinical and/or therapeutic inter-
vention or were stable according to clinical criteria, and patients
with post heart attack cardiopathy (control group) were enrolled.
All patients went through a baseline visit; only AF patients
underwent a follow up visit (at 3  1 months and 1 month for
unstable and stable patients respectively). At each visit, socio-
demographical and clinical information was gathered; AF-QoL,
SF-36 questionnaires and perception of general health status were
administered. AF-QoL is an 18-item questionnaire with 3
domains: psychological, physical and sexual. Questions refer to
previous month. Answers are 5 levels Likert-like. AF-QoL scores
range between 0–100,where 0 is poorHRQoL.RESULTS:A total
of 417 patients were included: 341 AF patients and 76 control
patients. Mean (SD) age was 61.2(12.4) and 31.4% were women.
AF type distribution was: 37.5% paroxysmal, 42.9% persistent
and 19.6% permanent. AF-QoL was completed by 88.5% of
patients. AF-QoL mean overall global score in AF patients was
43.6 and 51.7 in control group (p < 0.05). AF-QoL showed good
internal consistency (0.92) and good test-retest reliability (0.86) in
stable AF patients. Patients with more symptoms and worse
NYHA functional class at baseline and at the end of follow-up
visit showed lower scores in AF-QoL. AF-QoL correlations with
SF-36 and overall perception of general health status question
were moderate-high (0.32–0.69) and moderate (0.49) (p < 0.01)
repectively. AF-QoL effect size scores in patients declaring health
status positive changes was 1.06, 0.2 for those with no changes
and 0.1 for patients with negative changes. CONCLUSIONS:
AF-Qol has shown to be feasible, valid, reliable and responsive to
clinical changes in the context of clinical practice.
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OBJECTIVES: To predict the percentage of patients achieving
multiple optimal lipid values (OLV) after one year of combina-
tion fenoﬁbric acid (FA) + statin therapy or statin monotherapy.
METHODS: A dyslipidemia outcomes model was used to predict
multiple OLV attainment (any 3 of 4 targets: total-C, LDL-C,
HDL-C, or TG) among a cohort of 1000 patients with multiple
lipid abnormalities (MLA). Optimal lipid levels for HDL-C
(value >40 mg/dL for men, >50 mg/dL for women), LDL-C
(value <130 mg/dL), TG (value <150 mg/dL), and total-C (value
<210 mg/dL) were based on U.S. clinical practice guidelines.
Baseline lipid values were simulated with National Health and
Nutrition Examination Survey data, used to determine the shape
of lipid distributions (gamma for TG and log normal for the
others) and the correlation between these parameters. Mean
initial and on-treatment lipid values were obtained from three
12-week FA/statin studies, where FA 135 mg co-administered
with atorvastatin, rosuvastatin, and simvastatin at low (20 mg,
10 mg, 20 mg, respectively) and moderate doses (40 mg, 20 mg,
40 mg, respectively) was compared to FA and corresponding
statin monotherapy doses. RESULTS: Compared to equivalent
statin monotherapy, the addition of FA 135 mg to low-dose
simvastatin, rosuvastatin, and atorvastatin was predicted to
result in 43% (678 vs. 473 per 1000), 31% (814 vs. 621 per
1000), and 43% (723 vs. 506 per 1\000) more patients simulta-
neously achieving multiple OLV. The number of patients pre-
dicted to achieve multiple OLV increased by 16%, 18% and 25%
with FA + moderate-dose simvastatin, rosuvastatin, and atorvas-
tatin over equivalent dose statin monotherapy, respectively.
CONCLUSIONS: Patients with MLA receiving statin mono-
therapy may require add-on treatment to achieve multiple lipid
targets. This analysis suggests that treatment with FA in combi-
nation with low- and moderate-dose statin therapy may enable
more patients to simultaneously achieve OLV compared to statin
monotherapy.
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OBJECTIVES: To assess the cost-effectiveness of ivabradine in
stable angina patients in the Dutch health care setting in 2007.
METHODS: A Markov model was developed to estimate the
cost-effectiveness of ivabradine. The analysis was performed for
stable angina patients, who currently are candidate for revascu-
larisation. Data sources used included 1) Ivabradine clinical trial
data, 2) Data of the Dutch Heart Foundation, and 3) Data of the
Euro Heart Survey (European Cardiology database). Further-
more, published literature, ofﬁcial Dutch price/tariff lists and
national population statistics are used. The time horizon of the
model was 5 years in order to capture the long-term economic
impact of ivabradine. RESULTS: The results show that the use of
ivabradine leads to additional drug costs of €3873 over a period
of 5 years, which are offset by a cost saving of €8699 due to fewer
revascularisations (€1210 in the ivabradine arm versus €9909 in
the revascularisation arm) over a period of 5 years. As a result the
A342 Abstracts
